Hong Kong Pharma Digital Technology (NASDAQ:HKPD) Stock Scheduled to Reverse Split on Monday, October 26th

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) shares are going to reverse split on the morning of Monday, October 26th. The 1-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, October 25th.

Hong Kong Pharma Digital Technology Trading Down 8.9%

NASDAQ HKPD opened at $0.10 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.86 and a quick ratio of 3.75. Hong Kong Pharma Digital Technology has a 52-week low of $0.08 and a 52-week high of $1.72. The business’s 50-day moving average price is $0.19 and its 200 day moving average price is $0.39.

Hong Kong Pharma Digital Technology (NASDAQ:HKPD) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.04) earnings per share (EPS) for the quarter. The company had revenue of $3.15 million during the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded Hong Kong Pharma Digital Technology from a “sell (d)” rating to a “sell (e+)” rating in a research note on Thursday, August 13th. One analyst has rated the stock with a Sell rating. According to MarketBeat, Hong Kong Pharma Digital Technology presently has an average rating of “Sell”.

Hong Kong Pharma Digital Technology Company Profile

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.